Skip to content

Meningitis Encephalitis: a Metagenomics-Based Etiology & Epidemiology Research

Meningitis Encephalitis: a Metagenomics-Based Etiology & Epidemiology Research (MEMBER Research)

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04724876
Acronym
MEMBER
Enrollment
300
Registered
2021-01-26
Start date
2020-12-31
Completion date
2023-06-30
Last updated
2021-01-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Central Nervous System Infections and Inflammations

Brief summary

Autoimmune encephalitis (AE) is caused by abnormal immune response mediated by autoimmune antibodies of patients, which can be detected by a serial of autoimmune antibodies\[4,5,6,7\]. At present, the traditional infection diagnosis mainly relies on microbial culture method, which has the characteristics of long cycle, high cost, low detection rate and complex detection process. About 30-60% of encephalitis have unknown etiology\[2,3\]. On the other hand, the diagnosis and classification of noninfectious encephalitis mainly depend on the detection of autoimmune antibodies, the scope of diagnosis and differential diagnosis is limited, and the relationship between autoimmune encephalitis and infection factors is still unclear. Metagenomics sequencing (mNGS) is a new method that does not rely on microbial culture and can directly detect pathogenic nucleic acids. It has the characteristics of fast, accurate, high throughput, no preference for different pathogen detection, and can detect known and unknown pathogens at the same time. Nowadays, mNGS is widely used in the field of pathogen detection.

Interventions

None listed

Sponsors

Beijing Tiantan Hospital
CollaboratorOTHER
Air Force Military Medical University, China
CollaboratorOTHER
Peking Union Medical College Hospital
CollaboratorOTHER
The Second Hospital of Hebei Medical University
CollaboratorOTHER
First Affiliated Hospital, Sun Yat-Sen University
CollaboratorOTHER
Chinese PLA General Hospital
CollaboratorOTHER
Xuanwu Hospital, Beijing
CollaboratorOTHER
Third Affiliated Hospital, Sun Yat-Sen University
CollaboratorOTHER
Shandong Provincial Hospital
CollaboratorOTHER_GOV
Fudan University
CollaboratorOTHER
West China Hospital
CollaboratorOTHER
Henan Provincial People's Hospital
CollaboratorOTHER
Central South University
CollaboratorOTHER
The First Affiliated Hospital of Shanxi Medical University
CollaboratorOTHER
Beijing Tongren Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
14 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Either meet the items of 1, 2 or 1, 3 1. The patient's age \>14 years old, acute or subacute onset (less than 3 months), (first onset, treatment with anti-infection drugs and/or immunotherapy ≤5 days); 2. The patient has the following symptoms: 1. Dysmnesia, 2. Seizures, 3. Mental disorders, 4. Abnormal behavior, 5. Unconsciousness or coma, 6. Dyskinesia or involuntary movement, 7. lalopathy or be reticent, 8. Dysphagia, sleep disorders, or autonomic nervous dysfunction, 9. Ataxia. 3. Patients with meningeal irritation sign, intracranial hypertension and other manifestations, satisfy at least 3 of the following symptoms: 1. Headache, 2. Fever, 3. Stiff neck, 4. Disturbance of consciousness, 5. Kernig sign or brudzinski sign was positive.

Exclusion criteria

* 1\. Patients with suspected metabolic encephalopathy and toxic encephalopathy have the above manifestations, * 2\. Patients with central nervous system tumor (primary or metastatic) have the above manifestations, * 3\. The patient with non-organic mental illness, * 4\. Patients who had undergone brain surgery within 6 months have the above symptoms after operation, * 5\. Patients with traumatic brain injury have the above manifestations, * 6\. Febrile convulsions caused by non-cerebral causes, * 7\. Patients with above manifestations due to other reasons such as cerebrovascular disease, genetic disease, etc; * 8\. Patients who refuse lumbar puncture or have contraindications to lumbar puncture; * 9\. Patients who withdraw informed consent.

Design outcomes

Primary

MeasureTime frameDescription
To elucidate the etiology and epidemiology of CNS infection all around Chinawithin 2 weeksThe Investigators use mNGS method to describe central nervous system infection spectrum.

Countries

China

Contacts

Primary ContactJiawei Wang, Doctor
pengyujing1206@163.com18811612263

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026